IMGN News and Press, ImmunoGen Inc. From 01/04/23

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs. "Following the recent appro...

ImmunoGen ( NASDAQ: IMGN ) on Wednesday said it had appointed Renee Lentini as interim CFO, replacing Susan Altschuller. The company said it had started a search for Altschuller's permanent replacement. "(Altschuller) is on leave under the Family and Medical Leave Act (FMLA) and w...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, PhD, Senior Vice President and Chief Financial Officer (CFO), is on leave under the Family and Medical Leave Act (FMLA) and wil...

Oncology-focused biotech ImmunoGen ( NASDAQ: IMGN ) ended a four-day skid on Wednesday after William Blair pointed to guidelines from the National Comprehensive Cancer (NCCN) to support the potential of the company’s recently approved ovarian cancer therapy Elahere. Amid concer...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presenta...

ImmunoGen ( NASDAQ: IMGN ) and Biosion USA are collaborating to create antibody-drug conjugates (ADCs) for treating cancer. Under the research team up, Biosion will use its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies...

Broad Anti-Leukemia Activity in Relapsed/Refractory and Frontline AML Presented in Oral Session Recommended Phase 2 Dose Well-Tolerated; Determination of Optimal Venclexta Duration Ongoing in Separate Cohorts ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding fiel...

Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical collaboration with Gilead Science...

Palm Beach, FL – December 1, 2022 – FinancialNewsMedia.com News Commentary – The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or tissues in female reproductive organs called ovari...

Oncology-focused biotech ImmunoGen, Inc. ( NASDAQ: IMGN ) shed ~12% on Tuesday after the company said it would launch the newly approved ovarian cancer drug Elahere "in a matter of days" at a list price of $6,220 per vial. "Most patients receive 3 to 4 vials per cycle, w...